Changes in Hong Kong stocks | Keji Pharmaceutical-B (02171) rose more than 5% to release clinical data on Cykeizer, CT071, and CT0590 at the 66th American Society of Hematology

The Zhitong Finance App learned that Keji Pharmaceutical-B (02171) rose by more than 5%. As of press release, it had risen 5.26% to HK$4, with a turnover of HK$23.1038 million.

According to the news, Keji Pharmaceutical announced that it will present clinical data on Saekaize (Zevokie Orense injection, product number: CT053, an autologous CAR-T product targeting BCMA), CT071 (an autologous CAR-T cell candidate product targeting GPRC5D), and CT0590 (an allogeneic CAR-T cell candidate product targeting BCMA) at the 66th American Society of Hematology (“ASH”) annual meeting. The summary and further information will be announced after November 5, 2024 EST.

According to reports, Sikaize is a whole-human anti-autologous BCMACAR-T cell product used to treat multiple myeloma (MM). On February 23, 2024, the China Drug Administration approved the marketing application for Saikaize's new drug for the treatment of adult patients with recurrent or refractory multiple myeloma, which progressed after at least 3 lines of treatment (at least one proteasome inhibitor and immunomodulator had been used). Keji Pharmaceutical is advancing a phase 1b/2 clinical trial (LUMMICARSTUDY2) in North America to evaluate the safety and efficacy of Zewokiolensae injection in the treatment of recurrent or refractory multiple myeloma.